IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.
Zoe JohnsonChiara TarantelliElisa CivanelliLuciano CascioneFilippo SprianoAmy FraserPritom ShahTyzoon NomanbhoySara NapoliAndrea RinaldiKarolina Niewola-StaszkowskaMichael LahnDominique PerrinMathias WenesDenis MiglioriniFrancesco BertoniLars van der VeenGiusy Di ConzaPublished in: Cancer research communications (2023)
antitumor activity in various models with limited toxicity in animal studies provides the rationale for the ongoing trials in patients with solid tumors and hematologic cancers.